| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/02/2004 | US20040171842 VIRICIDES; uSING A SECONDARY AMIDE COMPOUNDAIDS |
| 09/02/2004 | US20040171839 Serine protease inhibitor; therapy for thrombosis , cardiovascular disorders |
| 09/02/2004 | US20040171835 Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient |
| 09/02/2004 | US20040171832 Novel sulfonate substituted pyrazol pyridine derivatives |
| 09/02/2004 | US20040171830 Carboline derivatives as pdev inhibitors |
| 09/02/2004 | US20040171828 Respiratory system disorders; asthma; antihistamines |
| 09/02/2004 | US20040171804 for drug screening cancer, osteoporosis, obesity, Alzheimer's disease drugs; genetic engineering; kits |
| 09/02/2004 | US20040171803 Artificial protein having potentiated immunogenicity of epitope |
| 09/02/2004 | US20040171697 Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy |
| 09/02/2004 | US20040171696 Formulations containing 2-(2-dimethylaminoethoxy)-2-phenyl-1,7,7-trimethylbicyclo[2.2.1]heptane (known as deramciclane); Parkinson's disease, Korsakoff syndrome, Huntington's disease |
| 09/02/2004 | US20040171695 Guanylhydrazones useful for treating diseases associated with T cell activation |
| 09/02/2004 | US20040171694 Inhibiting intestinal carbohydrate absorption without risk of diarrhea or dehydration |
| 09/02/2004 | US20040171693 Increasing dermal papilla cell proliferation using topical creatine formulation |
| 09/02/2004 | US20040171692 Modulation of bone formation |
| 09/02/2004 | US20040171691 Propofol with cysteine |
| 09/02/2004 | US20040171690 Use of protein essential aminoacids to treat amenorrhea and related disorders |
| 09/02/2004 | US20040171688 Inhibiting hepatocyte nuclear factor-4 alpha 1 controlled transcription; syndrome X, atherosclerosis, rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease; long chain fatty acylcoenzyme A |
| 09/02/2004 | US20040171686 Agent for prophylaxis or treatment of inflammatory bowel diseases |
| 09/02/2004 | US20040171685 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia |
| 09/02/2004 | US20040171684 Shelf stable verapamil hydrochloride formulations including carrier, antioxidant and chelant |
| 09/02/2004 | US20040171683 Method and materials for treatment of Alzheimer's disease |
| 09/02/2004 | US20040171681 Medicines and medicinal kits |
| 09/02/2004 | US20040171679 Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| 09/02/2004 | US20040171678 Reduced toxicity; blocking p-glycoprotein membrane toxin extrusion pump |
| 09/02/2004 | US20040171676 L-ascorbic acid-2-o-maleic acid-a-tocopherol diester 1-propanol adduct and process for producing the same |
| 09/02/2004 | US20040171674 Alpha-glucosidase inhibitors and their synthesis from a natural source |
| 09/02/2004 | US20040171673 increasing recovery rate and permanence of lean body mass without incident of hirsutism |
| 09/02/2004 | US20040171671 Cyclic ester of 3-hydroxybutyric acid; increasing cardiac efficiency, alternative glucose energy source, free radical scavenging |
| 09/02/2004 | US20040171670 Neurological diseases and disorders; such as 3-fluoro-10,11-dihydro-5-(2-aminoethyl)-5H-dibenzo[a,d]cycloheptene |
| 09/02/2004 | US20040171669 Rapid disintegration on contact with saliva forming easy to swallow palatable suspension; tablets |
| 09/02/2004 | US20040171668 Reducing side effects, lowering neurotoxicity; longer lasting antitumor action |
| 09/02/2004 | US20040171667 Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans |
| 09/02/2004 | US20040171666 Rapid, thorough absorption; eliminates gastrointestional disorder and reduces central nervous system stimulation side effects; low cost |
| 09/02/2004 | US20040171665 Novel polymorphic form IV and solvate; precipitation from ethyl acetate |
| 09/02/2004 | US20040171664 Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event |
| 09/02/2004 | US20040171663 Neuropathy, nephropathy, ophthalmopathy, arteriosclerosis; long lasting; single, low level daily dosage |
| 09/02/2004 | US20040171660 Single dose aromatase inhibitor for treating infertility |
| 09/02/2004 | US20040171659 Methods for treating diabetes |
| 09/02/2004 | US20040171658 Blood coagulation factor Xa inhibition; such as 2-O-(3'-amidinobenzyl)-5-O-(3''-amidinophenyl)-1,4:3,6-dianhydrosorbitol |
| 09/02/2004 | US20040171657 Disinfecting with oxathiazolone derivatives; fabrics, hair, skin, hard surfaces |
| 09/02/2004 | US20040171652 Dual-function microbicides |
| 09/02/2004 | US20040171650 Fighting parasitic infections in human and animals; 1,2,4-triazol-3-thioyl derivatives |
| 09/02/2004 | US20040171649 Intermediates for anthranilic amide insecticides and blood coagulation factor Xa inhibitors |
| 09/02/2004 | US20040171647 Reducing adverse side effects using optically pure S form |
| 09/02/2004 | US20040171646 Novel substituted benzimidazole dosage forms and method of using same |
| 09/02/2004 | US20040171645 Treating extrapyramidal movement disorder adverse effects of antiparkinson's drugs |
| 09/02/2004 | US20040171643 Acylaminothiazole derivatives, their preparation and therapeutic use |
| 09/02/2004 | US20040171641 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) |
| 09/02/2004 | US20040171639 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists |
| 09/02/2004 | US20040171637 anticancer agents; in admixture with one or more pharmaceutically acceptable carriers or diluents and a known chemotherapeutic agent |
| 09/02/2004 | US20040171636 Treatment of viral infections |
| 09/02/2004 | US20040171632 Combination chemotherapy |
| 09/02/2004 | US20040171631 Orally administered analgesic compositions containing nalbuphine |
| 09/02/2004 | US20040171630 both receptor-type and non-receptor type tyrosine kinases; to treat angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, |
| 09/02/2004 | US20040171629 Method and compounds for inhibition of cell death |
| 09/02/2004 | US20040171628 Benzo [g] quinoline derivatives for treating glaucoma and myopia |
| 09/02/2004 | US20040171627 quinazolinone derivatives, especially halofuginone, can also inhibit the pathophysiological processes of renal fibrosis in vivo, including the effect on both the glomeruli and the tubuli interstitial compartments |
| 09/02/2004 | US20040171625 transdermal formulations comprise a skin penetration enhancer; transdermal formulation, which is topically applied to an area of skin superficial to a carotid artery, a temporal artery, a vertebral artery, or to a tender spot associated with a head |
| 09/02/2004 | US20040171624 Pharmaceutical composition for treating mood disorders |
| 09/02/2004 | US20040171623 thieno[2,3-d]pyrimidinediones; modulation of autoimmune disease |
| 09/02/2004 | US20040171622 Cardioprotective delta opioid receptor agonists and methods of using same |
| 09/02/2004 | US20040171621 Novel crystalline forms of gatifloxacin and processes for preparation |
| 09/02/2004 | US20040171620 Nitrogen-containing bicyclic heterocycles for use as antibacterials |
| 09/02/2004 | US20040171619 Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient |
| 09/02/2004 | US20040171618 Compounds as PDE IV and TNF-inhibitors |
| 09/02/2004 | US20040171617 treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer |
| 09/02/2004 | US20040171616 preventing and treating thrombotic conditions, such as coronary artery disease, cerebrovascular disease, and other coagulation related disorders |
| 09/02/2004 | US20040171614 Novel gamma secretase inhibitors |
| 09/02/2004 | US20040171613 Therapeutic agent for non-immediate type allergic diseases |
| 09/02/2004 | US20040171612 Novel compounds with analgesic effect |
| 09/02/2004 | US20040171611 crystal modification of an active substance is important to the reproducible active substance content of a preparation |
| 09/02/2004 | US20040171610 treating a patient for sleep disorders |
| 09/02/2004 | US20040171609 Delivery of diazepam through an inhalation route |
| 09/02/2004 | US20040171607 Chemical compounds |
| 09/02/2004 | US20040171606 antagonism/inhibition, of the D3 receptor; substance abuse. |
| 09/02/2004 | US20040171605 Benzoxazepines derivatives and their use as ampa receptor stimulators |
| 09/02/2004 | US20040171601 Photodynamic and sonodynamic therapy |
| 09/02/2004 | US20040171599 Use of a pharmaceutically acceptable cellulose derivative to inhibit or reduce crystal growth of ascomycin |
| 09/02/2004 | US20040171598 administering an effective amount of a formulation free of classical preservatives and comprising a glucocorticoid; anecortave acetate |
| 09/02/2004 | US20040171597 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| 09/02/2004 | US20040171596 Prodrugs for use as ophthalmic agents |
| 09/02/2004 | US20040171595 new process for the preparation of a key intermediate |
| 09/02/2004 | US20040171594 Use of bis-acid(5-androsten-17-one-3beta-hydroxyl)diester for manufacture pharmaceuticals |
| 09/02/2004 | US20040171593 Method and compositions for treating an inflammatory disease |
| 09/02/2004 | US20040171592 reduced gastric effects; salicylic acid derivatives |
| 09/02/2004 | US20040171591 Method for decreasing low density lipoprotein |
| 09/02/2004 | US20040171589 Differential delivery of nitric oxide |
| 09/02/2004 | US20040171585 amphipathic carboxylate is capable of being endogenously converted to its respective coenzyme A thioester |
| 09/02/2004 | US20040171584 formulations of ANGIOTENSIN II AT1 receptors antagonists, using the cyclodextrins or their derivatives, lipossomes and the biodegradable polymers; increasing the bio-availability of losartan |
| 09/02/2004 | US20040171583 Compositions of plant carbohydrates as dietary supplements |
| 09/02/2004 | US20040171582 comprises a lysophosphatidic acid (LPA) receptor modulator; EDG-2 agonist or antagonist |
| 09/02/2004 | US20040171581 Polysaccharidic esters of retinoic acid |
| 09/02/2004 | US20040171579 anticoagulant piscine glucosaminoglycans; coating agent for invasive medical equipment |
| 09/02/2004 | US20040171578 in particular of inflammatory and hyperproliferative skin diseases, and cutaneous manifestations of immunologically induced diseases |
| 09/02/2004 | US20040171577 Aryl phosphate derivatives of d4T having anti-HIV activity |
| 09/02/2004 | US20040171576 with the proviso that the anticholinergic agent is not a tiotropium salt; asthma, chronic obstructive pulmonary disease |
| 09/02/2004 | US20040171572 Complex cationic lipids having quaternary nitrogens therein |
| 09/02/2004 | US20040171568 oligonucleotide at least 29 nucleotides in length, wherein the anti-HIV activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action |
| 09/02/2004 | US20040171565 vaccines that express derivatives of ADP-ribosyltransferase toxins that display significantly reduced, or are deficient in, intrinsic ADP-ribosyltransferase activity (i.e. herein referred to as mARTs) and yet retain adjuvanticity |
| 09/02/2004 | US20040171561 storage-stable mixture of a benzoyl peroxide dispersion, clindamycin or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier |